

10th East Asia Oncology Phase I Trials Conference (EA-TOPIC) April 20 - 21, 2024, Taipei, Taiwan

April 20, 2024	Topic	Speaker	Moderator
08:30 - 09:00AM	Registration for First Session		
09:00 - 09:15AM	Opening Remark	James Chih-Hsin Yang National Taiwan University Cancer Center, Taipei, Taiwan Toshihiko Doi National Cancer Center Hospital East, Kashiwa, Chiba, Japan	
09:15 - 09:45AM	How to Develop New Drugs in Nasopharyngeal Carcinoma?	Brigette B.Y. Ma Prince of Wales Hospital, Shatin, Hong Kong, China	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan
09:45 - 10:15AM	Immunotherapy Combination: What Went Wrong?	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan	Li-Yuan Bai China Medical University Hospital, Taichung, Taiwan
10:15 - 10:30AM	Group Photo		
10:30 - 11:00AM	Coffee Break		
11:00 - 11:30AM	Targeting KRAS: Anti-EGFR Antibodies Plus KRAS G12C Inhibitors as an Example	Yasutoshi Kuboki National Cancer Center Hospital East, Kashiwa, Chiba, Japan	Chih-Hung Hsu National Taiwan University Hospital, Taipei, Taiwan
11:30 - 11:45AM	Pharmaceutical Company Pipeline: Gilead Sciences	Bernard M. Fine Gilead Sciences, Foster City, CA, USA	Yen-Shen Lu National Taiwan University Hospital, Taipei, Taiwan
11:45 - 12:00PM	Pharmaceutical Company Pipeline: DXd-ADC Franchise and Next Wave	Lillian Chiu Daiichi Sankyo Taiwan, Taipei, Taiwan	Yen-Shen Lu National Taiwan University Hospital, Taipei, Taiwan
12:00 - 12:15PM	Pharmaceutical Company Pipeline: Eli Lilly / Loxo	Michael D. Axelson Loxo Oncology, Princeton, NJ, USA	Chiun Hsu National Taiwan University Cancer Center, Taipei, Taiwan
12:15 - 02:00PM	Lunch Break		
02:00 - 02:30PM	Targeting MTAP: PRMT5 Inhibitors and MAT2A Inhibitors as an Example	Jordi Rodon Ahnert MD Anderson Cancer Center, Houston, TX, USA	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan
02:30 - 02:45PM	Pharmaceutical Company Pipeline: Nuvalent	Viola W. Zhu Nuvalent, Cambridge, MA, USA	Jin-Yuan Shih National Taiwan University Hospital, Taipei, Taiwan
02:45 - 03:00PM	Pharmaceutical Company Pipeline: Voronoi	Sunghwan Kim Voronoi, Incheon, South Korea	Jin-Yuan Shih National Taiwan University Hospital, Taipei, Taiwan
03:00 - 03:15PM	Pharmaceutical Company Pipeline: Roche / Genentech	Nai-Shun (Nancy) Yao Genentech, South San Francisco, CA, USA	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan
03:15 - 03:45PM	Coffee Break		
03:45 - 04:15PM	Targeting TP53: MDM2 Inhibitors as an Example	Noboru Yamamoto National Cancer Center Hospital, Tokyo, Japan	Gee-Chen Chang Chung Shan Medical University Hospital, Taichung, Taiwan
04:15 - 04:45PM	Optimizing the Safety of Novel Antibody-Drug Conjugates - What Is New on Antibody-Drug Conjugates?	Toshio Shimizu Wakayama Medical University Hospital, Wakayama, Japan	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan
04:45 - 05:00PM	Pharmaceutical Company Pipeline: Pfizer / Seagen	Harald A. Weber Pfizer, Zug, Switzerland	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan
05:00 - 05:15PM	Wrap-Up of Day One	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan	

10th East Asia Oncology Phase I Trials Conference (EA-TOPIC) April 20 - 21, 2024, Taipei, Taiwan

April 21, 2024	Topic	Speaker	Moderator
08:30 - 08:45AM	Registration for Second Session		
08:45 - 09:00AM	Highlight of Day One	Chia-Chi (Josh) Lin National Taiwan University Cancer Center, Taipei, Taiwan	
09:00 - 09:30AM	Oncolytic Virus, a Novel Immunotherapy: OBP301 as an Example	Toshihiko Doi National Cancer Center Hospital East, Kashiwa, Chiba, Japan	Ann-Lii Cheng National Taiwan University Cancer Center, Taipei, Taiwan
09:30 - 10:00AM	Targeting AXL: Targeted Therapy or Immunotherapy?	Yuki Katsuya National Cancer Center Hospital, Tokyo, Japan	Kun-Huei Yeh National Taiwan University Hospital, Taipei, Taiwan
10:00 - 10:15AM	Group Photo		
10:15 - 11:00AM	Coffee Break		
11:00 - 11:30AM	How to Establish an Oncology Phase I Trials' Center in Malaysia?	Pei-Jye Voon Hospital Umum Sarawak, Kuching, Sarawak, Malaysia	Chien-Chung Lin National Cheng Kung University Hospital, Tainan, Taiwan
11:30 - 11:45AM	Pharmaceutical Company Pipeline: Amgen	Kopei Chang Amgen Taiwan, Taipei, Taiwan	Tom Wei-Wu Chen National Taiwan University Hospital, Taipei, Taiwan
11:45 - 12:00PM	Pharmaceutical Company Pipeline: PharmaEngine	Brian Shen PharmaEngine, Taipei, Taiwan	Tom Wei-Wu Chen National Taiwan University Hospital, Taipei, Taiwan
12:00 - 12:15PM	Closing Remark	James Chih-Hsin Yang National Taiwan University Cancer Center, Taipei, Taiwan Toshihiko Doi National Cancer Center Hospital East, Kashiwa, Chiba, Japan	